Electroconvulsive Therapy (ECT) increases serum Brain Derived Neurotrophic Factor (BDNF) in drug resistant depressed patients. 2006

Luisella Bocchio-Chiavetto, and Roberta Zanardini, and Marco Bortolomasi, and Maria Abate, and Matilde Segala, and Mario Giacopuzzi, and Marco Andrea Riva, and Eleonora Marchina, and Patrizio Pasqualetti, and Jorge Perez, and Massimo Gennarelli
Genetics Unit, IRCCS Centro S. Giovanni di Dio Fatebenefratelli, Via Pilastroni 4, 25123 Brescia, Italy. genetica@fatebenefratelli.it

Several findings have suggested that the neurotrophin BDNF could contribute to clinical efficacy of antidepressant treatments. The purpose of this study was to analyse if ECT operates a modulation of serum BDNF levels in a sample of drug resistant depressed patients. The results obtained show significantly higher serum levels of BDNF following ECT. More specifically, while no change occurred in the whole sample between T0 (baseline) and T1 (after ECT) (p=0.543) a significant increase has been identified at T2, one month after the end of ECT (p=0.002). However, the BDNF augmentation was evident even between T0 and T1 in a subgroup of patients who has low baseline BDNF levels. Although future researches are needed, the results herein presented show for the first time that ECT is associated with changes in serum BDNF and further support the possible involvement of BDNF in antidepressant therapies.

UI MeSH Term Description Entries
D008137 Longitudinal Studies Studies in which variables relating to an individual or group of individuals are assessed over a period of time. Bogalusa Heart Study,California Teachers Study,Framingham Heart Study,Jackson Heart Study,Longitudinal Survey,Tuskegee Syphilis Study,Bogalusa Heart Studies,California Teachers Studies,Framingham Heart Studies,Heart Studies, Bogalusa,Heart Studies, Framingham,Heart Studies, Jackson,Heart Study, Bogalusa,Heart Study, Framingham,Heart Study, Jackson,Jackson Heart Studies,Longitudinal Study,Longitudinal Surveys,Studies, Bogalusa Heart,Studies, California Teachers,Studies, Jackson Heart,Studies, Longitudinal,Study, Bogalusa Heart,Study, California Teachers,Study, Longitudinal,Survey, Longitudinal,Surveys, Longitudinal,Syphilis Studies, Tuskegee,Syphilis Study, Tuskegee,Teachers Studies, California,Teachers Study, California,Tuskegee Syphilis Studies
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003865 Depressive Disorder, Major Disorder in which five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Symptoms include: depressed mood most of the day, nearly every daily; markedly diminished interest or pleasure in activities most of the day, nearly every day; significant weight loss when not dieting or weight gain; Insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss of energy nearly every day; feelings of worthlessness or excessive or inappropriate guilt; diminished ability to think or concentrate, or indecisiveness, nearly every day; or recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt. (DSM-5) Depression, Involutional,Major Depressive Disorder,Melancholia, Involutional,Paraphrenia, Involutional,Psychosis, Involutional,Depressive Disorders, Major,Involutional Depression,Involutional Melancholia,Involutional Paraphrenia,Involutional Paraphrenias,Involutional Psychoses,Involutional Psychosis,Major Depressive Disorders,Paraphrenias, Involutional,Psychoses, Involutional
D004361 Drug Tolerance Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from DRUG RESISTANCE wherein an organism, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug. It should also be differentiated from MAXIMUM TOLERATED DOSE and NO-OBSERVED-ADVERSE-EFFECT LEVEL. Drug Tolerances,Tolerance, Drug,Tolerances, Drug
D004565 Electroconvulsive Therapy Electrically induced CONVULSIONS primarily used in the treatment of severe AFFECTIVE DISORDERS and SCHIZOPHRENIA. Convulsive Therapy, Electric,ECT (Psychotherapy),Electroshock Therapy,Shock Therapy, Electric,Convulsive Therapies, Electric,Electric Convulsive Therapies,Electric Convulsive Therapy,Electric Shock Therapies,Electric Shock Therapy,Electroconvulsive Therapies,Electroshock Therapies,Shock Therapies, Electric,Therapies, Electric Convulsive,Therapies, Electric Shock,Therapies, Electroconvulsive,Therapies, Electroshock,Therapy, Electric Convulsive,Therapy, Electric Shock,Therapy, Electroconvulsive,Therapy, Electroshock
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

Luisella Bocchio-Chiavetto, and Roberta Zanardini, and Marco Bortolomasi, and Maria Abate, and Matilde Segala, and Mario Giacopuzzi, and Marco Andrea Riva, and Eleonora Marchina, and Patrizio Pasqualetti, and Jorge Perez, and Massimo Gennarelli
April 2009, Neuroscience letters,
Luisella Bocchio-Chiavetto, and Roberta Zanardini, and Marco Bortolomasi, and Maria Abate, and Matilde Segala, and Mario Giacopuzzi, and Marco Andrea Riva, and Eleonora Marchina, and Patrizio Pasqualetti, and Jorge Perez, and Massimo Gennarelli
November 2022, International journal of psychiatry in clinical practice,
Luisella Bocchio-Chiavetto, and Roberta Zanardini, and Marco Bortolomasi, and Maria Abate, and Matilde Segala, and Mario Giacopuzzi, and Marco Andrea Riva, and Eleonora Marchina, and Patrizio Pasqualetti, and Jorge Perez, and Massimo Gennarelli
May 2009, European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology,
Luisella Bocchio-Chiavetto, and Roberta Zanardini, and Marco Bortolomasi, and Maria Abate, and Matilde Segala, and Mario Giacopuzzi, and Marco Andrea Riva, and Eleonora Marchina, and Patrizio Pasqualetti, and Jorge Perez, and Massimo Gennarelli
December 2009, Psychiatry research,
Luisella Bocchio-Chiavetto, and Roberta Zanardini, and Marco Bortolomasi, and Maria Abate, and Matilde Segala, and Mario Giacopuzzi, and Marco Andrea Riva, and Eleonora Marchina, and Patrizio Pasqualetti, and Jorge Perez, and Massimo Gennarelli
September 2006, Progress in neuro-psychopharmacology & biological psychiatry,
Luisella Bocchio-Chiavetto, and Roberta Zanardini, and Marco Bortolomasi, and Maria Abate, and Matilde Segala, and Mario Giacopuzzi, and Marco Andrea Riva, and Eleonora Marchina, and Patrizio Pasqualetti, and Jorge Perez, and Massimo Gennarelli
March 2016, Brain research bulletin,
Luisella Bocchio-Chiavetto, and Roberta Zanardini, and Marco Bortolomasi, and Maria Abate, and Matilde Segala, and Mario Giacopuzzi, and Marco Andrea Riva, and Eleonora Marchina, and Patrizio Pasqualetti, and Jorge Perez, and Massimo Gennarelli
March 2011, The journal of ECT,
Luisella Bocchio-Chiavetto, and Roberta Zanardini, and Marco Bortolomasi, and Maria Abate, and Matilde Segala, and Mario Giacopuzzi, and Marco Andrea Riva, and Eleonora Marchina, and Patrizio Pasqualetti, and Jorge Perez, and Massimo Gennarelli
July 2003, Biological psychiatry,
Luisella Bocchio-Chiavetto, and Roberta Zanardini, and Marco Bortolomasi, and Maria Abate, and Matilde Segala, and Mario Giacopuzzi, and Marco Andrea Riva, and Eleonora Marchina, and Patrizio Pasqualetti, and Jorge Perez, and Massimo Gennarelli
January 2008, Journal of affective disorders,
Luisella Bocchio-Chiavetto, and Roberta Zanardini, and Marco Bortolomasi, and Maria Abate, and Matilde Segala, and Mario Giacopuzzi, and Marco Andrea Riva, and Eleonora Marchina, and Patrizio Pasqualetti, and Jorge Perez, and Massimo Gennarelli
September 2023, Journal of clinical medicine,
Copied contents to your clipboard!